Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Consensus Recommendation of “Hold” from Brokerages

Gossamer Bio, Inc. (NASDAQ:GOSS) has received an average rating of “Hold” from the nine analysts that are currently covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, three have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $3.20.

A number of research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating on shares of Gossamer Bio in a research note on Monday, July 27th. Weiss Ratings restated a “sell (e+)” rating on shares of Gossamer Bio in a research note on Friday, August 14th. Finally, Leerink Partners raised shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 price target on the stock in a report on Tuesday, July 28th.

Gossamer Bio Stock Performance

NASDAQ GOSS opened at $0.20 on Wednesday. The business’s fifty day moving average is $0.17 and its 200 day moving average is $0.44. Gossamer Bio has a fifty-two week low of $0.11 and a fifty-two week high of $3.87. The company has a market capitalization of $48.00 million, a PE ratio of -0.29 and a beta of 2.04.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.08) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.04. The company had revenue of $9.24 million during the quarter, compared to analysts’ expectations of $3.63 million. On average, sell-side analysts forecast that Gossamer Bio will post -0.56 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Legal & General Group Plc bought a new position in Gossamer Bio in the 2nd quarter worth $26,000. Banco BTG Pactual S.A. bought a new stake in Gossamer Bio during the second quarter valued at about $27,000. Soltis Investment Advisors LLC bought a new stake in Gossamer Bio during the fourth quarter valued at about $31,000. MMA Asset Management LLC purchased a new position in shares of Gossamer Bio in the fourth quarter valued at about $31,000. Finally, Beacon Pointe Advisors LLC purchased a new position in shares of Gossamer Bio in the fourth quarter valued at about $34,000. Hedge funds and other institutional investors own 81.23% of the company’s stock.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.